Course of Diabetic Retinopathy in Untreated Fellow Eyes in RIDE and RISE: A Post Hoc Analysis

被引：3

作者：

Bakri, Sophie J. ^{[1
]}

Malhotra, Mila ^{[2
]}

Stoilov, Ivaylo ^{[2
]}

机构：

[1] Mayo Clin, 200 First St SW, Rochester, MN 55905 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

来源：

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2022年 / 53卷 / 04期

关键词：

INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; BEVACIZUMAB; PROGRESSION; SEVERITY;

D O I：

10.3928/23258160-20220311-03

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

BACKGROUND AND OBJECTIVE: To characterize diabetic retinopathy (DR) progression without therapy. PATIENTS AND METHODS: This post hoc analysis of the phase 3 RIDE and RISE trials examined the association between baseline DR severity on rates of >_ 2-step DR progression and improvement in untreated fellow eyes (n = 530) and ranibizumab-treated study eyes (n = 369). Kaplan-Meier analyses estimated progression to proliferative DR (PDR) over 2 years in eyes with nonproliferative DR (NPDR) at baseline. RESULTS: At month 24, 28.8% of untreated fellow eyes with moderately severe to severe NPDR at baseline experienced >_ 2-step DR progression, versus 10.3% of eyes with absent to moderate NPDR and 0 eyes with mild-to high-risk proliferative DR. Of the untreated fellow eyes with moderately severe to severe NPDR, 18.9% achieved >_ 2-step DR improvement, compared with 88.4% of ranibizumab-treated eyes. CONCLUSION: Without treatment, patients with moderately severe to severe NPDR are at risk of rapid disease progression and vision loss.

引用

页码：202 / 207

页数：6

共 19 条

[11] Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and Progression [J].

Ip, Michael S. ;

Domalpally, Amitha ;

Hopkins, J. Jill ;

Wong, Pamela ;

Ehrlich, Jason S. .

ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (09) :1145-1152

[12]

Lucentis, 2018, LUC PACK INS

[13] Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies [J].

Mitchell, Paul ;

McAllister, Ian ;

Larsen, Michael ;

Staurenghi, Giovanni ;

Korobelnik, Jean-Francois ;

Boyer, David S. ;

Do, Diana, V ;

Brown, David M. ;

Katz, Todd A. ;

Berliner, Alyson ;

Vitti, Robert ;

Zeitz, Oliver ;

Metzig, Carola ;

Lu, Chengxing ;

Holz, Frank G. .

OPHTHALMOLOGY RETINA, 2018, 2 (10) :988-996

[14] Diabetic Retinopathy Preferred Practice Pattern® [J].

Olsen, Timothy W. ;

Al-Rajhi, Ali ;

Ambrus, Andre ;

Daly, Meghan ;

Lum, Flora C. .

OPHTHALMOLOGY, 2020, 127 (01) :P66-P145

[15] Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE [J].

Quan Dong Nguyen ;

Brown, David M. ;

Marcus, Dennis M. ;

Boyer, David S. ;

Patel, Sunil ;

Feiner, Leonard ;

Gibson, Andrea ;

Sy, Judy ;

Rundle, Amy Chen ;

Hopkins, J. Jill ;

Rubio, Roman G. ;

Ehrlich, Jason S. .

OPHTHALMOLOGY, 2012, 119 (04) :789-801

[16] Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye [J].

Sugimoto, Masahiko ;

Nunome, Takayasu ;

Sakamoto, Rie ;

Kobayashi, Maki ;

Kondo, Mineo .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (08) :1543-1550

[17]

Wykoff CC., 2020, PANORAMA PHASE 3 DOU

[18]

Wykoff CC., 2019, ANG EX DEG 2019 FEBR

[19] Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy [J].

Wykoff, Charles C. ;

Eichenbaum, David A. ;

Roth, Daniel B. ;

Hill, Lauren ;

Fung, Anne E. ;

Haskova, Zdenka .

OPHTHALMOLOGY RETINA, 2018, 2 (10) :997-1009

← 1 2 →